Inflammatory bowel disease

• The Impact of the CB2 Cannabinoid Receptor in Inflammatory Diseases: An Update (02 Sep 2024)
  
• AS1/MMP25 interaction reduces neutrophil infiltration and intestinal epithelial injury in HIV/SIV infection (29 Aug 2024)
  
• Therapeutic Use of Cannabis in Inflammatory Bowel Disease (27 Aug 2024)
  
• Cannabinoid Therapeutic Effects in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (27 Aug 2024)
  
• A Crosstalk between the Cannabinoid Receptors and Nociceptin Receptors in Colitis—Clinical Implications (27 Aug 2024)
  
• Epigenetic Regulation of Cannabinoid-Mediated Attenuation of Inflammation and Its Impact on the Use of Cannabinoids to Treat Autoimmune Diseases (20 Aug 2024)
  
• Cannabinoids in Medicine: A Multifaceted Exploration of Types, Therapeutic Applications, and Emerging Opportunities in Neurodegenerative Diseases and Cancer Therapy (13 May 2024)
  
• Beyond Pain Relief: A Review on Cannabidiol Potential in Medical Therapies (27 Feb 2023)
  
• Beta-Caryophyllene Exhibits Anti-Proliferative Effects through Apoptosis Induction and Cell Cycle Modulation in Multiple Myeloma Cells (27 Nov 2022)
  
• Cannabinoids in Medicine: Cancer, Immunity, and Microbial Diseases (27 Aug 2022)
  
• Endocannabinoid System as a Promising Therapeutic Target in Inflammatory Bowel Disease – A Systematic Review (21 Jul 2022)